Samuel Vijaya Paul, Gupta Gaurav, Dahiya Rajiv, Jain Dev Anand, Mishra Anurag, Dua Kamal
Department of Anatomy, RAK College of Medicine, RAK Medical and Health Sciences University, Ras Al Khaimah, UAE.
School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, 302017, Jaipur, India.
Crit Rev Eukaryot Gene Expr. 2019;29(6):529-537. doi: 10.1615/CritRevEukaryotGeneExpr.2019027836.
Resveratrol has several therapeutic effects and is a nutraceutical. It was shown to imitate caloric restriction effects, exert anti-inflammatory and antioxidative effects, and affect the development and progression of many diseases through several mechanisms. While there is a wealth of evidence in vitro and in vivo that resveratrol could be a promising therapeutic agent, its potential must be confirmed by preclinical studies and clinical trials. We analyzed the current available preclinical and clinical data on resveratrol's pharmacological action. The bulk of resveratrol's preclinical studies and clinical trials focused on cancer, neurological disorders, cardiovascular diseases, diabetes, nonalcoholic fatty liver disease (NAFLD), and obesity. The latest preclinical studies and clinical trials reported that resveratrol was well tolerated and beneficially influenced biomarkers of disease for neurological disorders, cardiovascular diseases, and diabetes. Nevertheless, in certain types of cancers and in NAFLD, resveratrol had unclear and sometimes even detrimental effects. The major obstacle posed in most preclinical studies and clinical trials was the low bioavailability of resveratrol. This work thus provides useful guidelines for future preclinical and clinical resveratrol study planning and design.
白藜芦醇具有多种治疗作用，是一种营养保健品。研究表明，它能模拟热量限制的效果，发挥抗炎和抗氧化作用，并通过多种机制影响多种疾病的发生发展。虽然在体外和体内有大量证据表明白藜芦醇可能是一种有前景的治疗药物，但其潜力仍需通过临床前研究和临床试验来证实。我们分析了目前关于白藜芦醇药理作用的临床前和临床数据。白藜芦醇的大多数临床前研究和临床试验集中在癌症、神经疾病、心血管疾病、糖尿病、非酒精性脂肪性肝病（NAFLD）和肥胖症上。最新的临床前研究和临床试验报告称，白藜芦醇耐受性良好，对神经疾病、心血管疾病和糖尿病的疾病生物标志物有有益影响。然而，在某些类型的癌症和NAFLD中，白藜芦醇的作用尚不清楚，有时甚至有不利影响。大多数临床前研究和临床试验中面临的主要障碍是白藜芦醇的生物利用度低。因此，这项工作为未来白藜芦醇的临床前和临床研究规划与设计提供了有用的指导方针。
